Literature DB >> 6717893

Radiosensitization of Meth-A fibrosarcoma in mice by Lonidamine.

J H Kim, A Alfieri, S H Kim, C W Young, B Silvestrini.   

Abstract

Isogenic male BALB/c mice bearing Meth-A tumors in the ascites form were used. The effects of Lonidamine and irradiation both alone and in combination were studied. Lonidamine administered intraperitoneally produced a significant enhancement of irradiation effects.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6717893     DOI： 10.1159/000225883

Source DB:  PubMed          Journal:  Oncology        ISSN： 0030-2414            Impact factor:   2.935


  14 in total

1.  Phase II study of lonidamine in metastatic prostatic carcinoma.

Authors:  D J Stewart; S E Aitken; A H Irvine; D E Moors; N G Futter
Journal:  Invest New Drugs       Date:  1991-11       Impact factor: 3.850

2.  Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Authors:  G N Schwartz; B A Teicher; J P Eder; T Korbut; S A Holden; G Ara; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  The combined use of radiation therapy and lonidamine in the treatment of brain metastases.

Authors:  L M DeAngelis; V E Currie; J H Kim; G Krol; M A O'Hehir; F M Farag; C W Young; J B Posner
Journal:  J Neurooncol       Date:  1989-09       Impact factor: 4.130

4.  Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.

Authors:  K W Rosbe; T W Brann; S A Holden; B A Teicher; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin.

Authors:  Kavindra Nath; David S Nelson; Daniel F Heitjan; Dennis B Leeper; Rong Zhou; Jerry D Glickson
Journal:  NMR Biomed       Date:  2014-12-12       Impact factor: 4.044

6.  Mechanism of action of lonidamine in the 9L brain tumor model involves inhibition of lactate efflux and intracellular acidification.

Authors:  O Ben-Yoseph; J C Lyons; C W Song; B D Ross
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

7.  Kinetic and survival response of the M14 cell line to lonidamine associated with adriamycin or hyperthermia.

Authors:  G Starace; G Badaracco; A Bertuzzi; A Gandolfi; C Greco; M D Totaro; R Vitelli; G Zupi
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

Review 8.  Mechanism of antineoplastic activity of lonidamine.

Authors:  Kavindra Nath; Lili Guo; Bethany Nancolas; David S Nelson; Alexander A Shestov; Seung-Cheol Lee; Jeffrey Roman; Rong Zhou; Dennis B Leeper; Andrew P Halestrap; Ian A Blair; Jerry D Glickson
Journal:  Biochim Biophys Acta       Date:  2016-08-04

9.  The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters.

Authors:  Bethany Nancolas; Lili Guo; Rong Zhou; Kavindra Nath; David S Nelson; Dennis B Leeper; Ian A Blair; Jerry D Glickson; Andrew P Halestrap
Journal:  Biochem J       Date:  2016-02-01       Impact factor: 3.857

10.  Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.

Authors:  R J Popert; J R Masters; M Coptcoat; G Zupi
Journal:  Urol Res       Date:  1995
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.